Market Overview

UPDATE: Canaccord Genuity Reiterates Perrigo Company at Buy on Launch of Generic Mucinex

Related PRGO
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Benzinga's Top Upgrades
Tracking Ruane, Cunniff & Goldfarb's Portfolio - Q3 2015 Update (Seeking Alpha)

Canaccord Genuity maintained Perrigo Company (NASDAQ: PRGO) at Buy with a $128.00 price target.

Canaccord Genuity analyst Randall Stanicky commented, "Perrigo announced this morning the launch of its generic Mucinex 600mg ER tablets ($135M LTM brand sales). Although timing was as expected, we see the launch as a positive for the stock given the prior delay caused by validation issues and what should equate to a ~$40M annual revenue opportunity, or about ~$0.10 to EPS on a full-year basis with what is more incremental benefit anticipated for the March quarter (which we already expect to be strong). […] Trading at ~18.3x NTM P/E, we have yet to see the valuation mean revert, offering room for further multiple expansion."

Perrigo Company closed at $115.98 on Friday.

Latest Ratings for PRGO

Nov 2015B. RileyUpgradesBuy
Nov 2015UBSUpgradesNeutralBuy
Oct 2015B. RileyMaintainsNeutral

View More Analyst Ratings for PRGO
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Analyst Ratings


Related Articles (PRGO)

View Comments and Join the Discussion!

Get Benzinga's Newsletters